Prevention of progression and regression of target organ damage. Future strategies;Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro

Revista Clinica Espanola

Volumn 211, Issue SUPPL. 1, 2011, Pages 8-14

  De La Sierra, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiorenal disease continuum; Cardiovascular disease; Organ lesion; Prevention; Renin angiotensin system; Residual risk

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK MANAGEMENT;

CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FORECASTING; HUMANS; MULTIPLE ORGAN FAILURE; RENIN-ANGIOTENSIN SYSTEM;

EID: 79953693004     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(11)70003-0     Document Type: Article

References (48)

1. M.D. Flather, S. Yusuf, L. Kober, M. Pfeffer, A. Hall, and G. Murray Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 2000 1575 1581 (Pubitemid 30240501)
2. R. Garg, and S. Yusuf Overview of randomized trial of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
3. PROGRESS Collaborative Group Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
4. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
5. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 1665
6. C. Sierra, and A. De la Sierra Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers Curr Opin Nephrol Hypertens 14 2005 435 441 (Pubitemid 41152705)
7. J. Cohn, G. Tognoni For the Val-HeFT Investigators A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Eng J Med 345 2001 1667 1675 (Pubitemid 33126822)
8. C.B. Granger, J.J. McMurray, S. Yusf, P. Held, E.L. Michelson, and B. Olofsson Effects of candesartan on in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the Charm-Alternative trial Lancet 362 2003 772 776 (Pubitemid 37093917)
9. The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
10. M.A. Pfeffer, J.J.V. McMurray, E.J. Velazquez, J.L. Rouleau, L. Køber, A.P. Maggioni For the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906 (Pubitemid 37409706)
11. The ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
12. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and U. de Faire Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003 (Pubitemid 34286536)
13. J. Schrader, S. Lüders, A. Kulschewski, F. Hammersen, K. Plate, and J. Berger Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES) Stroke 36 2005 1218 1226
14. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, and L. Hansson Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031 (Pubitemid 38781102)
15. K.H. Gradman, and R. Kad Renin inhibition in hypertension J Am Coll Cardiol 51 2008 519 528
16. V. Dzau The cardiovascular continuum and renin-angiotensin-aldosterone system blockade J Hypertens 23 suppl 1 2005 S9 S17
17. A. De la Sierra, L.M. Ruilope, A. Coca, and M. Luque-Otero Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos Med Clin 115 2000 41 45 (Pubitemid 30497844)
18. E. Falaschetti, M. Chaudhury, J. Mindell, and N. Poulter Continued improvement in hypertension management in England: results from the Health Survey for England 2006 Hypertension 53 2009 480 485
19. F. Nicotra, B. Wettermark, M.C. Sturkenboom, A. Parodi, R. Bellocco, and A. Ekbom Management of antihypertensive drugs in three European countries J Hypertens 27 2009 1917 1922
20. A. De la Sierra, and L.M. Ruilope ¿Es posible conseguir una mayor reducción de la morbimortalidad cardiovascular en los pacientes ya tratados con bloqueadores del sistema renin-angiotensina? Med Clin 135 2010 212 214
21. P.M. Kearney, M. Whelton, K. Reynolds, P.K. Whelton, and J. He Worldwide prevalence of hypertension: a systematic review J Hypertens 22 2004 11 19 (Pubitemid 38293521)
22. K. Wolf-Maier, R.S. Cooper, J.R. Banegas, S. Giampaoli, H.W. Hense, and M. Joffres Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States JAMA 289 2003 2363 2369 (Pubitemid 37430168)
23. J.R. Banegas, J. Segura, J. Sobrino, F. Rodríguez-Artalejo, A. De la Sierra, and J.J. De la Cruz Effectiveness of blood pressure control outside the medical setting Hypertension 49 2007 62 68 (Pubitemid 46360342)
24. K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Pyorala, and U. Keil Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 2009 929 940
25. A.V. Chobanian Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy N Engl J Med 361 2009 878 887
26. A. De la Sierra Blood pressure control in the hypertensive population. What else the doctor can do? J Hypertens 28 2010 1129 1130
27. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
28. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, and J.C. Fruchart Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
29. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696 (Pubitemid 39140624)
30. The ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
31. The ACCORD Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
32. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
33. P. Gæde, P. Vedel, N. Larsen, G.V.H. Jensen, H.H. Parving, and O. Pedersen Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes N Engl J Med 348 2003 383 393 (Pubitemid 36159355)
34. P. Gæde, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes N Engl J Med 358 2008 580 591 (Pubitemid 351214285)
35. P. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, and M. Caulfield Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
36. B. Dahlöf, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, and M. Caulfield Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906 (Pubitemid 41265663)
37. P. Sever, B. Dahlöf, N. Poulter, H. Wedel, G. Beevers, and M. Caulfield Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial Eur Heart J 27 2006 2982 2988 (Pubitemid 44950442)
38. N.K. Hollenberg, H.H. Parving, G. Viberti, G. Remuzzi, S. Ritter, and S. Zelenkofske Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 2007 1921 1926 (Pubitemid 47356634)
39. K. Rossing, K.J. Schjoedt, B.R. Jensen, F. Boomsma, and H.H. Parving Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 2005 1190 1198 (Pubitemid 43246436)
40. E. Burgess, N. Muirhead, P. Rene de Cotret, A. Chiu, V. Pichette, and S. Tobe Supramaximal dose of candesartan in proteinuric renal disease J Am Soc Nephrol 20 2009 893 900
41. J.J. McMurray, J. Östergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson Effects of candesartan on in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: the Charm-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
42. R. Kunz, C. Friedrich, M. Wolbers, and J.F. Mann Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 2008 30 48 (Pubitemid 351688350)
43. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg For the AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2008 2433 2446 (Pubitemid 351793017)
44. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, V. Shi For the ACCOMPLISH trial investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
45. G.L. Bakris, P.A. Sarafidis, M.R. Weir, B. Dahlöf, B. Pitt, K. Jamerson ACCOMPLISH Trial investigators Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 2010 1173 1181
46. G. Bakris, M. Molitch, A. Hewkin, M. Kipnes, P. Sarafidis, K. Fakouhi For the STAR Investigators Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome Diabetes Care 29 2006 2592 2597 (Pubitemid 44912184)
47. Y. Matsui, K. Eguchi, M.F. O'Rourke, J. Ishikawa, H. Miyashita, and K. Shimada Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients Hipertension 54 2009 716 723
48. M. Gorostidi, and A. De la Sierra Antagonistas de los receptores de la angiotensina II en combinación con antagonistas del calcio. Focus en la asociación de olmesartán con amlodipino Hipertens Riesgo Vasc 27 supl 2 2010 part I:16-21